Cite
APA Citation
Soubrier, M., Pereira, B., Frayssac, T., Fan, A., Couderc, M., Malochet-Guinamand, S., Mathieu, S., Tatar, Z., Tournadre, A., & Dubost, J. (n.d.). sAT0117 Retention rates of adalimumab, etanercept, and infliximab as 1st- or 2nd-line biotherapy for rheumatoid arthritis patients in daily practice in auvergne. Annals of the rheumatic diseases, 76, 813. http://access.bl.uk/ark:/81055/vdc_100135163270.0x000061